Lung Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Lung Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer [Phase 2]
This Phase 2 clinical trial evaluates stereotactic body radiation therapy with or without nivolumab for patients with Stage I-IIA or recurre…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas [Phase 2]
A Phase 2 clinical trial evaluating temozolomide plus SurVaxM (survivin long peptide vaccine) for progressing metastatic neuroendocrine carc…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. [Phase 3]
A Phase 3 trial is comparing radiotherapy to everolimus for somatostatin receptor-positive neuroendocrine tumors of the lung and thymus, and…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
An ongoing European Institute of Oncology trial is comparing thymic, pulmonary, and pancreatic well-differentiated high-grade neuroendocrine…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors [Phase 2]
CVM-1118 is being studied in a Phase 2 trial for advanced neuroendocrine tumors. The study is currently active but not recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: A Safety Study of 212Pb-Pentixather Radioligand Therapy [EARLY_Phase 1]
An early-phase safety study of the radioligand therapy 212Pb-Pentixather is not yet recruiting, evaluating its use for lung carcinoid tumors…
-
CLINICAL_TRIALS trial_result · 2025-01-06Clinical Trial Update: A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment [NA]
A completed study evaluating whether circulating tumor DNA can be used in follow-up of patients with advanced gastroenteropancreatic or lung…
-
CLINICAL_TRIALS research · 2024-06-18Clinical Trial Update: A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) [Phase 2]
Phase 2 clinical trial evaluating the activity and safety of combining cabozantinib with temozolomide in lung and gastroenteropancreatic neu…
-
CLINICAL_TRIALS trial_result · 2023-05-19Clinical Trial Update: Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors [Phase 1]
Phase 1 study evaluating the safety of the CHK1 inhibitor VX-970 (M6620) in combination with whole-brain radiation therapy for brain metasta…
-
CLINICAL_TRIALS trial_result · 2021-10-29Clinical Trial Update: Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours [Phase 3]
Phase 3 trial evaluating lanreotide autogel/depot 120 mg vs placebo in lung neuroendocrine tumors; study terminated with results posted.